Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 12Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Peripheral Blood Stem Cell Transplantation 85fludarabine phosphate 81Filgrastim 78Methotrexate 69Etoposide 68Cytarabine 62Rituximab 61Radiotherapy 56Cyclosporine 52Mycophenolic Acid 51Vincristine 50Whole-Body Irradiation 48Busulfan 46Tacrolimus 41Antilymphocyte Serum 40Melphalan 39Dexamethasone 39Prednisone 36Methylprednisolone 35Doxorubicin 35fludarabine 28Granulocyte Colony-Stimulating Factor 25Calcium Dobesilate 25merphos 24Leucovorin 23Cord Blood Stem Cell Transplantation 22sargramostim 18dexamethasone acetate 18dexamethasone 21-phosphate 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Liposomes × Other hematologic neoplasm × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡